Based on the findings from the Phase III clinical trials of inactivated SARS COV-2 Vaccine, (BBIBP-CORV) emergency use authorization (EUA) was granted for the vaccine to frontline workers in the UAE. A prospective cohort study was conducted among frontline workers to estimate the incidence rate and risk of symptomatic COVID-19 infection 14 days after the second dose of inoculation with BBIBP-CORV inactivated vaccine. Those who received two doses of the BBIBP-CORV vaccine in the period from 14th of September 2020 (first dose) to 21st of December 2020 (second dose) were followed up for COVID-19 infections. 11,322 individuals who received the two-dose BBIBP-CORV vaccine were included and were followed up post the second dose plus fourteen days. The incidence rate of symptomatic infection was 0.08 per 1000-person days (95% CI 0.07, 0.10). The estimated absolute risk of developing symptomatic infection was 0.97% (95% CI 0.77%, 1.17%). The confirmed seroconversion rate was 92.8%. There were no serious adverse events reported and no individuals suffered from severe disease. Our findings show that vaccinated individuals are likely to remain protected against symptomatic infection or becoming PCR positive for SARS COV 2 following the second dose of the vaccination.
【저자키워드】 Medical research, Epidemiology, Outcomes research, 【초록키워드】 COVID-19, Vaccine, vaccination, clinical trial, risk, prospective cohort study, Emergency use authorization, EUA, COVID-19 infection, Inactivated vaccine, inoculation, symptomatic, incidence rate, inactivated, BBIBP-CorV, symptomatic infection, dose, severe disease, phase, Serious Adverse Events, Serious Adverse Event, 95% CI, second dose, PCR positive, first dose, SARS CoV, COVID-19 infections, individual, seroconversion rate, vaccinated individuals, vaccinated individual, Phase III clinical trials, reported, conducted, suffered, the vaccine, 【제목키워드】 Infection, incidence of COVID-19, United Arab Emirate,